1 of 3
FEATURED COMPANIES
- Eidos Therapeutics
- NeuraImmune Therapeutics
- MORE
This “Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a disease caused by the destabilization of a transport protein called transthyretin which leads to the abnormal deposition of amyloid protein in the heart. The disease is characterized by the depositions of amyloid protein fibrils in the left ventricle walls, which is the main pumping chamber of the heart. ATTR-CM has two subtypes- wild type and hereditary type. The wild type ATTR-CM happens without mutation and is thought to occur due to aging and majorly affects men above the age of 60. The Hereditary ATTR-CM is said to occur due to the mutation in the transthyretin gene and may be observed in individuals in the 50-60 age group.
" Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape is provided which includes the disease overview and Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment guidelines. The assessment part of the report embraces, in depth Transthyretin Amyloid Cardiomyopathy (ATTR-CM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Drugs
Acoramidis (AG 10): Eidos Therapeutics
Eidos therapeutics’ drug candidate AG 10 is in the phase III stage of drug development currently. The molecule was designed to stabilize TTR by copying the T119M- TTR variant’s structure.
NI006: NeuraImmune Therapeutics
NI006, a NeuraImmune Therapeutics’ drug candidate is a human antibody that specifically targets only the disease-associated conformation of the amyloid protein. The drug molecule is capable of targeting boththe ATTR linked with hereditary ATTR-CM as well as the wild type. Currently, it is in the Phase I of the drug development.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Therapeutic Assessment
This segment of the report provides insights about the different Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
There are approx. 3+ key companies which are developing the therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The companies which have their Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage, i.e. phase III include, NeuraImmune Therapeutics and others.
The report covers around 3+ products under different phases of clinical development like
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a disease caused by the destabilization of a transport protein called transthyretin which leads to the abnormal deposition of amyloid protein in the heart. The disease is characterized by the depositions of amyloid protein fibrils in the left ventricle walls, which is the main pumping chamber of the heart. ATTR-CM has two subtypes- wild type and hereditary type. The wild type ATTR-CM happens without mutation and is thought to occur due to aging and majorly affects men above the age of 60. The Hereditary ATTR-CM is said to occur due to the mutation in the transthyretin gene and may be observed in individuals in the 50-60 age group.
" Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape is provided which includes the disease overview and Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment guidelines. The assessment part of the report embraces, in depth Transthyretin Amyloid Cardiomyopathy (ATTR-CM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Transthyretin Amyloid Cardiomyopathy (ATTR-CM) R&D. The therapies under development are focused on novel approaches to treat/improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
This segment of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Drugs
Acoramidis (AG 10): Eidos Therapeutics
Eidos therapeutics’ drug candidate AG 10 is in the phase III stage of drug development currently. The molecule was designed to stabilize TTR by copying the T119M- TTR variant’s structure.
NI006: NeuraImmune Therapeutics
NI006, a NeuraImmune Therapeutics’ drug candidate is a human antibody that specifically targets only the disease-associated conformation of the amyloid protein. The drug molecule is capable of targeting boththe ATTR linked with hereditary ATTR-CM as well as the wild type. Currently, it is in the Phase I of the drug development.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Therapeutic Assessment
This segment of the report provides insights about the different Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
There are approx. 3+ key companies which are developing the therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The companies which have their Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage, i.e. phase III include, NeuraImmune Therapeutics and others.
The report covers around 3+ products under different phases of clinical development like
- Late-stage products(Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Report Insights
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs?
- How many Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eidos Therapeutics
- NeuraImmune Therapeutics
- Acoramidis
- NI006
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Eidos Therapeutics
- NeuraImmune Therapeutics
- MORE
Introduction
Executive Summary
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview
In-depth Commercial Assessment
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Products
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Unmet Needs
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Market Drivers and Barriers
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Future Perspectives and Conclusion
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Analyst Views
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Companies
Appendix
List of Tables
Table 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM) companies' collaborations, Licensing, Acquisition - Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Products
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Unmet Needs
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Market Drivers and Barriers
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Future Perspectives and Conclusion
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Analyst Views
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Companies
Appendix
List of Tables
Table 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
- Eidos Therapeutics
- NeuraImmune Therapeutics
Note: Product cover images may vary from those shown
